@article{bfc55ad51b8c4560bd263fff2407fd33,
title = "DNA damage response at telomeres boosts the transcription of SARS-CoV-2 receptor ACE2 during aging",
abstract = "The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes the coronavirus disease 2019 (COVID-19), known to be more common in the elderly, who also show more severe symptoms and are at higher risk of hospitalization and death. Here, we show that the expression of the angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 cell receptor, increases during aging in mouse and human lungs. ACE2 expression increases upon telomere shortening or dysfunction in both cultured mammalian cells and in vivo in mice. This increase is controlled at the transcriptional level, and Ace2 promoter activity is DNA damage response (DDR)-dependent. Both pharmacological global DDR inhibition of ATM kinase activity and selective telomeric DDR inhibition by the use of antisense oligonucleotides prevent Ace2 upregulation following telomere damage in cultured cells and in mice. We propose that during aging telomere dysfunction due to telomeric shortening or damage triggers DDR activation and this causes the upregulation of ACE2, the SARS-CoV-2 cell receptor, thus contributing to make the elderly more susceptible to the infection.",
author = "Sara Sepe and Francesca Rossiello and Valeria Cancila and Fabio Iannelli and Valentina Matti and Giada Cicio and Matteo Cabrini and Eugenia Marinelli and Alabi, {Busola R.} and {di Lillo}, Alessia and {Di Napoli}, Arianna and Shay, {Jerry W.} and Claudio Tripodo and {d{\textquoteright}Adda di Fagagna}, Fabrizio",
note = "Funding Information: We thank Joachim Lingner and Marco Giorgio for sharing reagents and all F.d?A.d.F. laboratory members for discussions. S.S. is supported by Fondazione Umberto Veronesi (FUV) and was previously supported by SIPOD 2 (Structural International Post Doc Program 2)?the People Programme (Marie Curie Actions) of the European Union?s Seventh Framework Programme FP7 under grant agreement no 600399. F.d?A.d.F laboratory is supported by: ERC advanced grant (TELORNAGING?835103); AIRC-IG (21762); Telethon (GGP17111); AIRC 5X1000 (21091); ERC PoC grant (FIREQUENCER?875139); Progetti di Ricerca di Interesse Nazionale (PRIN) 2015 ?ATR and ATM-mediated control of chromosome integrity and cell plasticity?; Progetti di Ricerca di Interesse Nazionale (PRIN) 2017 ?RNA and genome Instability?; Progetto AriSLA 2021 ?DDR & ALS?; POR FESR 2014-2020 Regione Lombardia (InterSLA project); FRRB?Fondazione Regionale per la Ricerca Biomedica?under the frame of EJP RD, the European Joint Programme on Rare Diseases with funding from the European Union's Horizon 2020 research and innovation program under the EJP RD COFUND-EJP NO 825575. J.W.S. is supported by the lung cancer SPORE from NIH 50CA070907. The synopsis image has been created with BioRender.com. Funding Information: We thank Joachim Lingner and Marco Giorgio for sharing reagents and all F.d{\textquoteright}A.d.F. laboratory members for discussions. S.S. is supported by Fondazione Umberto Veronesi (FUV) and was previously supported by SIPOD 2 (Structural International Post Doc Program 2)—the People Programme (Marie Curie Actions) of the European Union{\textquoteright}s Seventh Framework Programme FP7 under grant agreement no 600399. F.d{\textquoteright}A.d.F laboratory is supported by: ERC advanced grant (TELORNAGING—835103); AIRC‐IG (21762); Telethon (GGP17111); AIRC 5X1000 (21091); ERC PoC grant (FIREQUENCER—875139); Progetti di Ricerca di Interesse Nazionale (PRIN) 2015 “ATR and ATM‐mediated control of chromosome integrity and cell plasticity”; Progetti di Ricerca di Interesse Nazionale (PRIN) 2017 “RNA and genome Instability”; Progetto AriSLA 2021 “DDR & ALS”; POR FESR 2014‐2020 Regione Lombardia (InterSLA project); FRRB—Fondazione Regionale per la Ricerca Biomedica—under the frame of EJP RD, the European Joint Programme on Rare Diseases with funding from the European Union's Horizon 2020 research and innovation program under the EJP RD COFUND‐EJP NO 825575. J.W.S. is supported by the lung cancer SPORE from NIH 50CA070907. The synopsis image has been created with BioRender.com. Publisher Copyright: {\textcopyright} 2021 The Authors. Published under the terms of the CC BY NC ND 4.0 license",
year = "2022",
month = feb,
day = "3",
doi = "10.15252/embr.202153658",
language = "English (US)",
volume = "23",
journal = "EMBO Reports",
issn = "1469-221X",
publisher = "Nature Publishing Group",
number = "2",
}